ClinicalTrials.gg
CompletedNCT01304537Updated Jun 9, 2016

Study of the Safety and Efficacy of Intravenous Alpha-1 Antitrypsin in Type 1 Diabetes Mellitus

A Phase 1/2 interventional study of Alpha-1 Antitrypsin 40mg (AAT, Glassia®) and Alpha-1 Antitrypsin 60mg (AAT, Glassia®) in Type 1 Diabetes Mellitus, sponsored by Kamada, Ltd.. Completed at 2 sites in Israel. Open to participants aged 10 Years to 25 Years. Per ClinicalTrials.gov, last updated 2016-06-09.

Sponsored by Kamada, Ltd. · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
10 Years to 25 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 140 studies in Diabetes Mellitus, Type 1 with a site in Israel — 19 open to participants now, 23 under way, 4 of them phase 3. Diabetes Mellitus, Type 1 · Israel.

Enrollment
93rd of 116
24 · median 75
Started
2011
with 8 others
Phase 1/2
3 of 140
none open now
Registered
36th of 140
by date

Among the 140 studies in Diabetes Mellitus, Type 1 with a site in Israel, this one is the 93rd largest by enrollment of the 116 interventional ones that give a count, is one of 9 that started in 2011, is one of 3 in phase 1/2, and was the 36th registered.

Diabetes Mellitus, Type 1

3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

19 of the 140 studies in Diabetes Mellitus, Type 1 with a site in Israel are open now. Recruiting first, the newest first:

14 more — sign in →

All 19 open studies →

A study can be open while its sites in Israel have not opened yet or have stopped. Only those recruiting at a site in Israel →

Who these studies take

Of the 414 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 260 (63%) stop at 75 or younger; 187 take children under 18; 64 take healthy volunteers.

This study: 10 Years to 25 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 140 studies in Diabetes Mellitus, Type 1 with a site in Israel, or all of them as a file.
02

Study summary

Alpha-1 Antitrypsin (AAT), trade name (Glassia ®), is being explored in this phase I/II trial as a potential disease modifying agent in Type 1 Diabetes Mellitus (T1DM) based on its anti-inflammatory properties. AAT is an acute stress reactant protein that increases during inflammation. In T1DM inflammation serves a major role in disease progression.

Read the detailed description

AAT is a protein produced by the human liver and secreted into the blood circulation. AAT, which belongs to a group of serine protease inhibitors (SERPINS) is an acute stress reactant protein that increases during stress conditions, including inflammation. AAT blocks serine proteases that enhance pro-inflammatory mediators (i.e. IL-1 alpha, IL-6, IL-8, TNFalpha) as well as induces production of anti-inflammatory mediators (i.e. IL-10 and IL-1-receptor antagonist).

In Type 1 Diabetes Mellitus (T1DM) inflammation serves a major role in disease progression. The inflammatory signature pattern in these patients appears to have been present years before clinical onset.

Although circulating levels of AAT in T1DM are normal, in majority of cases, the activity of AAT is severely compromised by non-enzymatic glycations, supporting the conclusion that serum protease inhibitory capacity is reduced in T1DM.

It has been shown in different studies, including in vivo and in vitro that AAT has a protective affect on pancreatic islets. This has been demonstrated in both decrease in progression of diabetes in the non-obese diabetic (NOD) mouse as well as during transplantation of islets which presented viability and activity (insulin production) in the presence of AAT. More specifically, islet cells are protected by human AAT from apoptosis, as shown by reduced caspase-3 activity after the addition of human AAT to islet culture media.

Based on the mentioned anti-inflammatory properties of AAT sided to in vivo and in vitro studied indicating that AAT may serve as a disease modifying agent in T1DM, the presented study is suggested.

03

Conditions studied

  • Type 1 Diabetes Mellitus
04

Who can participate

Ages eligible
10 Years to 25 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject (or parent/guardian) willing and able to sign an
  • Age 10-25 (inclusive) years
  • Diagnosed with T1DM within the previous 6 months
  • Level of C-peptide ≥ 0.2 pmol/mL during MMTT(maximal level)
  • Positive for at least one diabetes-related autoantibody(except for insulin autoantibody)
  • No significant abnormalities in serum hematology,serum chemistry according to the Investigator's judgment, taking into considerations the potential effects of the diabetic illness.
  • No significant abnormalities in urinalysis according to the Principal Investigator's judgment, taking into considerations the potential effects of the diabetic illness.
  • No significant abnormalities in per investigator judgment
  • Negative for and antibodies to , -1
  • Non-pregnant, non-lactating female patients, whose screening pregnancy test is negative and who are using methods deemed reliable by the investigator.

Exclusion criteria

Exclusion Criteria:

  • Subjects who have received an active/ within 4 weeks of the screening date
  • Subjects who have received treatment with medication within 2 months prior to screening or any or cytostatic agent within 6 months prior to screening
  • IgA deficient subjects
  • Individuals with a history of severe immediate reactions, including anaphylaxis, to plasma products
  • Planned major surgery within the study period
  • intercurrent illnesses, including(but not limited to): cardiac, hepatic, renal,neurological, hematological, neoplastic, immunological, skeletal or other) that in the opinion of the investigator, could interfere with the safety, compliance or other aspects of this study. Patients with well-controlled, chronic diseases could be possibly included after consultation with the treating physician and the sponsor.
  • Pregnant or lactating women at entry to study and those who are unwilling to agree to continue to use acceptable methods of throughout the study.
  • Presence of psychiatric/ mental disorder or any other medical disorder which might impair the patient's ability to give or to comply with the requirements of the study protocol.
  • Evidence of ongoing viral infection with , and/or -1.
  • Evidence of alcohol abuse or history of alcohol abuse or illegal and/or legally prescribed drugs.
  • Participation in another interventional clinical trial within 30 days prior to baseline visit.
  • Inability to attend scheduled clinic visits and/or comply with the study protocol.
  • Any other factor that, in the opinion of the investigator, would prevent the patient form complying with the requirements of the protocol.
  • Current use of any medication known to influence glucose tolerance (e.g., beta-blockers, angiotensin-converting enzyme inhibitors, interferons, quinidine anti-malarial drugs, lithium, niacin).
  • Current or prior (within the last 30 days prior to screening visit) use of metformin, sulfonylureas, glinides, thiazolidinediones, exenatide, liraglutide, DPP-IV inhibitors or amylin.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Alpha-1 Antitrypsin 40mg (AAT, Glassia®)

    Subjects in this arm will receive a dose of 40 mg/kg throughout the study.

    Drug: Alpha-1 Antitrypsin 40mg (AAT, Glassia®)

  • Experimental
    Alpha-1 Antitrypsin 60mg (AAT, Glassia®)

    Subjects in this arm will receive a dose of 60 mg/kg throughout the study.

    Drug: Alpha-1 Antitrypsin 60mg (AAT, Glassia®)

  • Experimental
    Alpha-1 Antitrypsin 80mg (AAT, Glassia®)

    Subjects in this arm will receive a dose of 80 mg/kg throughout the study.

    Drug: Alpha-1 Antitrypsin 80mg (AAT, Glassia®)

Interventions

06

What researchers measure

Primary outcomes

  1. Safety and Tolerability

    Safety and Tolerability: assessed by vital signs(systolic/diastolic blood pressure and heart rate), physical examination, routine safety lab tests, AEs and SAEs.

    Time frame: Approximately 1 year

Secondary outcomes

  1. Efficacy

    Pancreatic beta cell function ; External Insulin dose requirements; Glycosylated hemoglobin (HbA1c) levels.

    Time frame: Approximately 1 year

07

Study locations

2 sites
  • Institute for Endocrinology and Diabetes, National Center for Childhood Diabetes at Schneider Children's Medical Center of Israel
    Petach Tikva 49202, 49202, Israel
  • Assaf Haroffeh Medical Center
    Zerifin, 70300, Israel
08

References and documents

Publications

  • Ozeri E, Mizrahi M, Shahaf G, Lewis EC. alpha-1 antitrypsin promotes semimature, IL-10-producing and readily migrating tolerogenic dendritic cells. J Immunol. 2012 Jul 1;189(1):146-53. doi: 10.4049/jimmunol.1101340. Epub 2012 May 25. PubMed 22634621 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2011, a primary completion of Nov 2012 and a completion of Nov 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 24, 2011
First posted
Feb 25, 2011
Start
Jun 2011
Primary completionActual
Nov 2012
CompletionActual
Nov 2012
Last update
Jun 9, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 9, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01304537
Lead sponsor
Kamada, Ltd.
Responsible party
Sponsor
First posted
Feb 25, 2011
Start date
Jun 2011
Primary completion
Nov 2012
Completion
Nov 2012
Last update
Jun 9, 2016

Study contacts

Mariana Rachmiel, B.Med.Sc
principal investigator · Assaf Haroffeh Medical Center, Zerifin, Israel
Yael Lebenthal, MD
principal investigator · Institute for Endocrinology & Diabetes, Schneider Children's Medical Center, Israel

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Alpha 1-Antitrypsin

Start the discussion